• Shengnan Li, Shu Wang, Raghavan Murugan, Ali Al-Khafaji, Daniel J Lebovitz, Michael Souter, Susan R N Stuart, John A Kellum, and Monitoring Organ Donors to Improve Transplantation Results (MOnIToR) Study Investigators.
• Center for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States; Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China.
• J Crit Care. 2018 Dec 1; 48: 42-47.

PurposeWe sought to build prediction models for organ transplantation and recipient survival using both biomarkers and clinical information.Materials And MethodsWe abstracted clinical variables from a previous randomized trial (n = 556) of donor management. In a subset of donors (n = 97), we measured two candidate biomarkers in plasma at enrollment and just prior to explantation.ResultsSecretory leukocyte protease inhibitor (SLPI) was significant for predicting liver transplantation (C-statistic 0.65 (0.53, 0.78)). SLPI also significantly improved the predictive performance of a clinical model for liver transplantation (integrated discrimination improvement (IDI): 0.090 (0.009, 0.210)). For other organs, clinical variables alone had strong predictive ability (C-statistic >0.80). Recipient 3-years survival was 80.0% (71.9%, 87.0%). Donor IL-6 was significantly associated with recipient 3-years survival (adjusted Hazard Ratio (95%CI): 1.26(1.08, 1.48), P = .004). Neither clinical variables nor biomarkers showed strong predictive ability for 3-year recipient survival.ConclusionsPlasma biomarkers in neurologically deceased donors were associated with organ use. SLPI enhanced prediction within a liver transplantation model, whereas IL-6 before transplantation was significantly associated with recipient 3-year survival. Clinicaltrials.gov: NCT00987714.Copyright © 2018 Elsevier Inc. All rights reserved.

26 keywords...

hide…